Schizophrenia Stocks List

Related ETFs - A few ETFs which own one or more of the above listed Schizophrenia stocks.

Schizophrenia Stocks Recent News

Date Stock Title
Oct 4 LLY Eli Lilly (LLY) Rises But Trails Market: What Investors Should Know
Oct 4 BMY Bristol-Myers trades in the green for seventh straight session
Oct 4 LLY Pharma Stock Roundup: FDA Approves SNY's Dupixent for COPD & More
Oct 4 AZN Pharma Stock Roundup: FDA Approves SNY's Dupixent for COPD & More
Oct 4 LLY Hims & Hers Health Asserts Demand For Its Compounded Weight Loss Offering To Continue Despite Resolved Supply Shortages
Oct 4 BMY Q3 pharma and biotech layoffs in charts: More than 1000 each in July and August
Oct 4 BMY UMB to refile $6.4B lawsuit against Bristol-Myers by end of next week - report
Oct 4 LLY What end of Eli Lilly's weight-loss drug shortage means for the competition
Oct 4 LLY Eli Lilly's Mounjaro, Zepbound removed from FDA's shortage list
Oct 4 LLY England's NHS Proposes Phased Rollout of Eli Lilly's Mounjaro, Considers Digital Services to Boost Access
Oct 4 LLY AbbVie Cuts 2024 Earnings Guidance to Include Acquisition Costs
Oct 4 AZN AbbVie Cuts 2024 Earnings Guidance to Include Acquisition Costs
Oct 4 LLY NHS proposes phased launch for Eli Lilly’s Mounjaro
Oct 4 BMY Bristol Myers' $10B Cancer Drug Opdivo Scores Expanded Use FDA Approval For Lung Cancer In Pre And Post-Surgery Setting
Oct 4 LLY As Weight-Loss Drugs Battle, Upstart Viking Therapeutics Threatens Eli Lilly, Novo Nordisk, Pfizer
Oct 4 AZN Thermo Fisher plant making Astra/ Sanofi RSV drug reportedly breached FDA rules
Oct 4 LLY Top T. Rowe Price Fund Manager Shares Her Secrets
Oct 4 BMY Opdivo gets ‘perioperative’ approval; pharmas cut jobs in New Jersey, Ireland
Oct 4 LLY Texas sues major PBMs, pharma companies over high insulin prices
Oct 4 LLY Ozempic for all, Zepbound is back, and the top CEO pay: Pharma news roundup
Schizophrenia

Schizophrenia is a mental disorder characterized by abnormal behavior, strange speech and a decreased ability to understand reality. Other symptoms include false beliefs, unclear or confused thinking, hearing voices that do not exist, reduced social engagement and emotional expression and lack of motivation. People with schizophrenia often have additional mental health problems such as anxiety, depressive or substance-use disorders. Symptoms typically come on gradually, begin in young adulthood and in many cases never resolve.The causes of schizophrenia include environmental and genetic factors. Possible environmental factors include being raised in a city, cannabis use during adolescence, certain infections, the age of a person's parents, and poor nutrition during pregnancy. Genetic factors include a variety of common and rare genetic variants. Diagnosis is based on observed behavior, the person's reported experiences and reports of others familiar with the person. During diagnosis, a person's culture must also be taken into account. As of 2013, there is no objective test. Schizophrenia does not imply a "split personality" or dissociative identity disorder, conditions with which it is often confused in public perception.The mainstay of treatment is antipsychotic medication, along with counselling, job training and social rehabilitation. It is unclear whether typical or atypical antipsychotics are better. In those who do not improve with other antipsychotics, clozapine may be tried. In more serious situations where there is risk to self or others, involuntary hospitalization may be necessary, although hospital stays are now shorter and less frequent than they once were.About 0.3% to 0.7% of people are affected by schizophrenia during their lifetimes. In 2013, there were an estimated 23.6 million cases globally. Males are more often affected and on average experience more severe symptoms. About 20% of people eventually do well, and a few recover completely; about 50% have lifelong impairment. Social problems, such as long-term unemployment, poverty and homelessness, are common. The average life expectancy of people with the disorder is 10–25 years less than that of the general population. This is the result of increased physical health problems and a higher suicide rate (about 5%). In 2015, an estimated 17,000 people worldwide died from behavior related to, or caused by, schizophrenia.

Browse All Tags